One small biotech holds the key to a revolution in treating Alzheimer's disease. Jeff Bezos, Goldman Sachs & Big Pharma giants have invested billions into this unknown biotech. Our research proves that anyone who gets in today could see gains as high as 113,000%!

Ollin Sykes Biography and Net Worth

Director of 89bio

Ollin B. Sykes is Independent Director of Charles & Colvard, LTD. Since 1984, he has served as the President of Sykes & Company, P.A., a regional accounting firm specializing in accounting, tax, and financial advisory services. Mr. Sykes earned his Bachelor of Science degree in accounting at Mars Hill College and is a Certified Public Accountant, a Certified Information Technology Professional, and a Certified Management Accountant. Mr. Sykes served as a director of Hampton Roads Bankshares, Inc. (NASDAQ: HMPR), a financial holding company operating in North Carolina, Maryland eastern shore, and Virginia, from December 2008 until December 31, 2010. He currently serves as a director of Bank of Hampton Roads, a wholly owned subsidiary of Hampton Roads Bankshares, Inc. Our Board has determined that Mr. Sykes’s background in accounting and finance and his accounting certifications qualify him to serve on the Board of Directors.

What is Ollin B. Sykes' net worth?: The estimated net worth of Ollin B. Sykes is at least $15.37 million as of March 1st, 2024. Mr. Sykes owns 1,863,398 shares of 89bio stock worth more than $15,373,034 as of April 26th. This net worth approximation does not reflect any other investments that Mr. Sykes may own. Learn More about Ollin B. Sykes' net worth.
How do I contact Ollin B. Sykes?: The corporate mailing address for Mr. Sykes and other 89bio executives is 142 SANSOME STREET SECOND FLOOR, SAN FRANCISCO CA, 94104. 89bio can also be reached via phone at 415-432-9270 and via email at [email protected]. Learn More on Ollin B. Sykes' contact information.
Has Ollin B. Sykes been buying or selling shares of 89bio?: Ollin B. Sykes has not been actively trading shares of 89bio within the last three months. Learn More on Ollin B. Sykes' trading history.
Who are 89bio's active insiders?: 89bio's insider roster includes Gregory Grunberg (Director), Ryan Martins (CFO), Rohan Palekar (CEO), Ollin Sykes (Director), and Ram Waisbourd (Insider). Learn More on 89bio's active insiders.
Are insiders buying or selling shares of 89bio?: In the last twelve months, 89bio insiders bought shares 1 times. They purchased a total of 1,350,000 shares worth more than $20,722,500.00. In the last twelve months, insiders at the sold shares 5 times. They sold a total of 51,910 shares worth more than $942,909.15. The most recent insider tranaction occured on March, 4th when Director Ra Capital Management, L.P. bought 1,350,000 shares worth more than $20,722,500.00. Insiders at 89bio own 4.4% of the company. Learn More about insider trades at 89bio.
Information on this page was last updated on 3/4/2024.

Ollin B. Sykes Insider Trading History at 89bio

Ollin B. Sykes Buying and Selling Activity at 89bio

89bio Company Overview

89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia. The company was incorporated in 2018 and is headquartered in San Francisco, California.

Today's Range

Now: $8.25

$8.04

$8.46

50 Day Range

MA: $11.03

$8.25

$13.77

2 Week Range

Now: $8.25

$6.57

$22.93

Volume

1,011,846 shs

Average Volume

1,228,915 shs

Market Capitalization

$785.57 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.04

The World's First "$20 Trillion Drug?"

From Behind the Markets | Ad

Get the name of the stock here >>>